DENVER -- The two-drug combination of doravirine and islatravir was as efficacious as the three-drug regimen of bictegravir, ...

Researchers at Queen Mary University of London have led the clinical development of the first non-integrase strand-transfer inhibitor (INSTI) single tablet treatment for HIV, among growing concern for ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, * today announced data from its phase 1 study of long-acting formulations of VH184, ...

Adults with HIV and obesity who switched from an antiretroviral therapy (ART) regimen with an integrase strand transfer inhibitor (INSTI) and tenofovir alafenamide to doravirine with or without ...

Weight gain associated with integrase strand transfer inhibitor-based antiretroviral therapy (ART) may be mitigated or reversed over time by switching to protease inhibitor-based ART. For patients ...

Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain experienced by participants taking Dovato ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data highlighting the breadth of its innovative HIV treatment research pipeline. The ...

ACC017 showed significant reductions in HIV-RNA levels in ART-naïve patients, with no viral breakthrough or adverse events reported. The safety profile of ACC017 was comparable to placebo, with no ...

SEATTLE--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced data from a Phase 2 study evaluating the efficacy, safety and tolerability of a combination of bictegravir (75 mg) (BIC) ...

Background. Integrase strand transfer inhibitors (INSTIs) are crucial for the treatment of human immunodeficiency virus (HIV) type 2 infection, due to limited available therapeutic options. Recently, ...